> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guidance on ANDA Labeling After RLD is Withdrawn
- URL: https://www.fdaweb.com/guidance-on-anda-labeling-after-rld-is-withdrawn/
- Published: 2016-07-11T12:00:00.000Z
- Updated: 2026-09-14T21:13:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136146

*Federal Register* Notice: FDA is making available a draft guidance for industry entitled *Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn*. It describes a process for updating labeling for ANDAs in cases where FDA has withdrawn approval of the NDA for the ANDA’s reference listed drug for reasons other than safety or effectiveness. To download this guidance, click [here.](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510240.pdf?ref=fdaweb.com) To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-07-11/pdf/2016-16157.pdf?ref=fdaweb.com)